Assisted Reproduction Techniques

Challenges and Management Options

Khaldoun Sharif, Arri Coomarasamy, Khaldoun Sharif, Arri Coomarasamy

• Editorial: Wiley-Blackwell
• Año: 2021
• ISBN:
  9781119622123
• Edición: 2
• Categoría: Medicine
• Categoría: Gynecology, Obstetrics & Midwifery

Assisted reproduction techniques have led to the birth of 8 million babies worldwide

Assisted reproduction techniques (ART), in particular in-vitro fertilization and intra-cytoplasmic sperm injection, are the most advanced forms of infertility treatment. They involve numerous counseling, medical, surgical and laboratory-based steps. At each step various problems and complications could be encountered that challenge even the most experienced ART practitioners. Moreover, patients with complex medical disorders may require ART, presenting further challenges.

Assisted Reproduction Techniques will stimulate resourceful thinking in the ART practitioner when faced with these challenges. It outlines various management options, the reasoning behind them, and the evidence on which they are based to enable the practitioner to choose the most suitable solution for the needs of each patient.

Written by 171 internationally renowned experts, Assisted Reproduction Techniques follows the patient's journey throughout the whole ART process, with chapters on:

• Counseling and preparation
• Pituitary suppression and ovarian stimulation
• Oocyte retrieval
• Embryo transfer
• The luteal phase
• The ART laboratory
• The male patient
• The ART pregnancy
• General and organizational issues

Each of the 116 concise chapters includes clinical cases, background, evidence-based practical management options, preventive measures, key-point summaries of the important details and answers to questions patients ask.

Assisted Reproduction Techniques first edition has established its place as a "must read" for ART trainees and practitioners alike, and in this second edition all chapters have been updated, with the addition of new ones addressing training issues, organizational and business skills, and social media use in ART.

SECTION ONE
Counseling and preparation

1
Risk of cancer from ovarian stimulation

Yadava Jeve

Birmingham Women’s Hospital, Birmingham, UK

Case History: A 36‐year‐old woman had controlled ovarian stimulation as part of IVF treatment, resulting in a term pregnancy 2 years previously. Following that, her mother developed breast cancer at the age of 61 years. Now the patient desires another pregnancy, but she is concerned about the risk of cancer due to ovarian stimulation. How should she be counseled?

Background

Women suffering from subfertility are often concerned about the safety of the drugs and the risk of cancer. A belief that using hormones could increase the risk of cancer is one of the most significant fears. In recent years, there have been many debates about the relationship between infertility, fertility drugs and cancer. Early studies raised substantial concern with ovulation‐stimulating drugs being linked with large increases in ovarian cancer [1,2]. However, it is difficult to separate cancer risk after fertility treatment from the underlying condition of infertility. Comorbidities such as obesity, excessive smoking, anovulation, endometriosis and nulliparity are frequently related to subfertility, but they are also independently related to an increased risk of cancer [3]. The delay or the inability to achieve a pregnancy is an important risk factor for breast, endometrial and ovarian cancer. However, the relationship between infertility treatment and cancer incidence remains an open question [2,4].

Management options

Breast cancer

Breast cancer is the most common malignancy in women, affecting one in eight women. Breast cancer is a multifactorial disease; however, most breast cancers are hormone‐dependent [5]. Compared with a normal menstrual cycle, estradiol concentration increases up to tenfold in ovulation stimulation cycle [6]. Therefore, the effect of subfertility and its treatment on breast cancer is widely investigated in the literature. The association between polycystic ovary syndrome (PCOS) and breast cancer has been examined in several studies. Meta‐analysis showed that PCOS does not increase the risk of breast cancer [7, 8].

As for fertility drugs and breast cancer risk, some studies showed no association while others demonstrated a possible increase in risk [9–12]. An Australian study (n = 21,025) showed commencing IVF treatment at a young age (less than 24 years of age) is associated with an increased rate of breast cancer [13]. It is expected that, if ovulation induction per se causes breast cancer, such tumors may have distinct characteristics such as strong estrogen receptor expression, but a study showed that breast cancer diagnosed within the first 2 years following infertility treatment is similar in tumor characteristics such as tumor size and histological types, estrogen receptor, progesterone receptor and Her2/Neu expression status compared to those occurring in patients without prior infertility treatment [14].

Women with BRCA1 or BRCA2 mutation have an increased risk of breast cancer. A study of 1,550 BRCA1 and 964 BRCA2 mutation carriers did not show any evidence that ovarian stimulation for IVF increases the breast cancer risk in BRCA1/2 mutation carriers [15]. A large UK‐based data linkage cohort study of 255,786 women did not find an increase in the overall risk of breast cancer but a small increase in the risk of in situ breast cancer was reported [16]. A meta‐analysis of eight cohort studies showed IVF treatment does not increase the breast cancer risk [17]. A total of seven systematic reviews or meta‐analyses evaluated the relationship between fertility drugs and breast cancer []. They have either shown no increase in the risk of breast cancer or a decrease in risk following infertility treatment. Therefore, as per the American Society of Reproductive Medicine guideline, women could be reassured that fertility drugs are not associated with an increased risk of breast cancer [24].

Ovarian cancer

Ovulation is considered to be a potential biologic promoter of ovarian cancer, which is called the “incessant ovulation” hypothesis. A second hypothesis is that gonadotropin stimulation increases the risk of malignant changes directly, or by acting in combination with a raised concentration of estrogen. Yet another hypothesis frequently suggested by epidemiological data is that undiagnosed early ovarian cancer causes, in some manner, infertility [25]. Data from 12 case‐control studies conducted in the period 1956–1986 showed pregnancy, breastfeeding and oral contraceptive use induce biological changes that protect against ovarian malignancy. A small fraction of the excess ovarian cancer risk among nulliparous women was due to infertility [26]. Only 3 of the 12 studies examined the association between the use of fertility drugs and invasive ovarian cancer. One study showed an increased risk of ovarian cancer in infertile women who had used fertility drugs. This study had several limitations. Subsequently, a large cohort study [27] suggested an increased risk of invasive and borderline ovarian tumors, a finding that was supported by other studies [28,29]. A pooled analysis of case‐control studies showed fertility drug use in nulligravid women was associated with borderline serous tumors but not with any invasive histologic subtypes [30]. Several other epidemiological studies showed no convincing association between the use of fertility drugs and risk of ovarian cancer [18,31–34].

An important group of women who are at increased risk of developing ovarian cancer are those with BRCA1 and BRCA2 gene mutations. Recent studies suggested that BRCA mutation carriers may have decreased ovarian reserve compared with women without BRCA mutations [35,36]. The studies suggested that treatment for infertility does not significantly increase the risk of ovarian cancer among women with a BRCA mutation [37,38]. A meta‐analysis of nine cohort studies ...